{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"117","upperLimit":"117","value":"117"},{"groupId":"OG001","lowerLimit":"90","upperLimit":"262","value":"116"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG000","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG001","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received intravenous topotecan during consolidation cycle 1 and had PK samples collected were included in this analysis. Per protocol, low- and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.","reportingStatus":"POSTED","timeFrame":"Pre-infusion, 5 min., 1, 3, and 24 hours from end of infusion","title":"Topotecan AUC0-24h in Consolidation Chemotherapy","type":"SECONDARY","unitOfMeasure":"µg·h/L"}